logo-loader
viewNEXTLEAF SOLUTIONS Ltd.

Nextleaf Solutions wins patents in three European countries for CBD oil extraction technology

The company’s method of extracting and separating cannabinoids and terpenes makes it possible to purify and concentrate the desired compounds, which can be used for the manufacturing of a diverse array of products

Patented stamp
The Vancouver-based company initially files its patents in the US to create a priority date and allow for future filings in other jurisdictions

Nextleaf Solutions Ltd (CSE:OILS) announced that it has been issued patents in Germany, France and the UK related to its CBD oil extraction technology.

The company’s method of extracting and separating cannabinoids and terpenes makes it possible to purify and concentrate the desired compounds, which can be used for the manufacturing of a diverse array of products standardized for dose, the company said.

Over the past year, the company has been granted 24 issued patents and possesses more than 60 pending patents related to the extraction, purification and formulation of cannabinoids. 

READ: Nextleaf Solutions issues shares under the Employee Equity Participation Plan implemented in response to the coronavirus pandemic

"Nextleaf's team of chemists and engineers have done a great job translating innovation into one of the largest stacks of IP for the industrial-scale extraction and distillation of CBD and THC," Nextleaf IP Director Taran Grey said in a statement. "It is an exciting time with commercial oil production commencing at Nextleaf Labs".

The new additions extend Nextleaf’s patent portfolio to encompass methodologies relating to the removal of fats and waxes from crude cannabis oil extracts in far less time, achieving more efficient throughput rates, and refined distillate.

Unrefined botanical extracts contain chlorophyll, fats, and other impurities that result in undesirable flavours and aromas when consumed, the company said. Nextleaf can apply its solution to a variety of primary extraction methods, such as supercritical CO2 or ethanol.

Securing patent protection in Europe, particularly in Germany and the UK, is central to Nextleaf’s long-term IP and commercial strategy, the company said. 

Germany exported the highest dollar value of pharmaceuticals of any country last year and had more sales of medical sales than all other European countries combined, Neatleaf noted.

The European patents mirror a patent previously granted by the US Patent and Trademark Office last year. The Vancouver-based company initially files its patents in the US to create a priority date and allow for future filings in other jurisdictions, the company said.

Contact Andrew Kessel at [email protected] 

Follow him on Twitter @andrew_kessel

Quick facts: NEXTLEAF SOLUTIONS Ltd.

Price: 0.265 CAD

CSE:OILS
Market: CSE
Market Cap: $28.9 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of NEXTLEAF SOLUTIONS Ltd. named herein, including the promotion by the Company of NEXTLEAF SOLUTIONS Ltd. in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Nextleaf Thought Leadership Series– "The state of IP in the cannabis...

Nextleaf Solutions (CSE: OILS-OTCQB: OILFF) CEO Paul Pedersen joined Steve Darling from Proactive Vancouver to discuss why the company has made it part of their mandate to protect their Intellectual Property with the issuance of patents. Pedersen also shared his thoughts about the cannabis...

1 week, 6 days ago

2 min read